期刊文献+

重组人血小板生成素治疗化疗相关血小板减少的临床价值 被引量:11

Value of recombinant human thrombopoietin in the treatmeat of chemotherapy-induced thrombocytopenia in patients with solid tumor
原文传递
导出
摘要 目的评价国产重组人血小板生成素(rhTPO)治疗实体瘤患者化疗后血小板(PLT)减少的临床疗效和安全性。方法采用非随机、平行对照的研究方法对化疗后PLT〈75×10^9/L的72例患者进行观察治疗。治疗组35例,采用国产rhTPO治疗,15000U/d,皮下注射;对照组37例,采用重组人白细胞介素11(rhIL-11)治疗,3mg/d,皮下注射。结果用药后,治疗组和对照组PLT的最低值分别为(46.2±20.3)×10^9/L和(37.2±16.7)×10^9/L,PLT恢复的最高值分别为(250.2±159.0)×10^9/L和(160.5±96.4)×10^9/L,两组差异均有统计学意义(均P〈0.05)。治疗组Ⅲ、Ⅳ度PLT减少的发生率和持续时间均明显低于对照组(均P〈0.05)。治疗组PLT输注4例,对照组PLT输注11例。治疗组不良反应的发生率(11.4%)明显低于对照组(78.4%,P〈0.001),且程度较轻。结论国产rhTPO能明显地减少PLT降低的程度和持续时间,更快地促进PI|T恢复,且患者不良反应轻,安全性好。 Objective To evaluate the efficacy and safety of domestically manufactured recombinant human thrombopoietin (rhTPO) in the treatment for chemotherapy-induced thrombocytopenia in patients with solid tumors. Methods A non-randomized controlled study was conducted. Seventy-two patients with platelet count 〈 75×10^9/L after chemotherapy were enrolled into this study according to the standard criteria of NCI-CTC toxicity stratification. Thirty-five patients in the treatment-group received subcutaneous injection of rhTPO at a dose of 15 000 U/d, another 37 patients in the control group received subcutaneous injection of rhIL-11 a at a dose of 3 mg/d as the paralleled control. Results The mean minimal platelet count after rhTPO treatment was (46.2 ±20.3 ) ×10^9/L in the treatment-group versus (37.2 ±16.7 ) ×10^9/L in the control-group ( P 〈 0.05 ), while the mean maximal platelet count was (250.2 ±159.0) ×10^9/L versus (160.5 ±96.4)×10^9/L (P 〈0.05). The incidence rate of adverse effects and duration of grade Ⅲ and Ⅳ thrombocytopenia in the treatment-group was also significantly lower than those in the control-group. Furthermore, the patients receiving platelet transfusion were 4/35 in the treatment-group versus 11/37 in the control-group ( P 〉 0.05). The side-effect rate in the treatment-group was significantly lower than that in the control-group ( 11.4% versus 78.4% , P 〈 0.01 ). Conclusion Compared with rhIL-11, administration of rhTPO after chemotherapy is safe and effective with mild adverse effects in reducing the degree and duration of thrombocytopenia.
出处 《中华肿瘤杂志》 CAS CSCD 北大核心 2008年第8期623-625,共3页 Chinese Journal of Oncology
关键词 血小板减少 重组人血小板生成素 重组白细胞介素-11 化学疗法 Thrombocytopenia Recombinant human thrombopoietin RhIL-11 Chemotherapy
  • 相关文献

参考文献10

二级参考文献47

  • 1王兴元,冯奉仪,宋三泰,王华庆,张茂宏,刘健,刘叙仪,许立功,张阳.国产重组人白介素-11衍生物治疗化疗所致血小板降低的多中心临床研究2006肿瘤防治新进展济南论坛征文通知[J].中华肿瘤杂志,2005,27(6):373-376. 被引量:35
  • 2Basser R. The impact of thrombopoietin on clinical practice. Curr Pharm Des, 2002, 8:369-377
  • 3Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia. J Clin Oncol, 2003, 21(16):3158-3167
  • 4Basser RL, O′Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood, 2002, 99 (7):2599 -2602
  • 5Jones DV Jr, Ashby M, Vadhan-Raj S, et al. Recombinant human thrombopoietin clinical development. Stem Cells,1998, 16(Suppl 2):199-206
  • 6Vadhan-Raj S, Murray LJ, Bueso-ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med, 1997, 126(9):673-681
  • 7Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Eng J Med, 1997, 336( 6 ) :404-409
  • 8Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al.Recombinant human thrombopoietin attenuates carboplatininduced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med, 2000, 132:364-368
  • 9Vadhan-Raj S. Recombinant human thrombopoietin in myelosuppressive chemotherapy. Oncology, 2001, 15(7 Suppl 8):35-38
  • 10Linker C, Anderlini P, Herzig R, et al. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. Biol Blood Marrow Transplant, 2003, 9(6):405-413

共引文献91

同被引文献138

引证文献11

二级引证文献91

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部